High-definition Gland Imaging
Utilizes Dynamic Meibomian Imaging (DMI) to distinctively image meibomian gland structure in high definition.

Example OS Image – Average Lipid Layer Thickness 100+nm

Nanometer Dynamic Lipid Layer Thickness
Features patented technology analyzing over one billion data points to isolate lipid layer of the tear film, measuring thickness to sub-micron levels.

Example Partial Blink

Blink Analysis
Evaluates dynamic response of the lipids to blinking, while proprietary algorithms measure the extent of lid closure during each blink.

DMI – Adaptive Transillumination

High-definition Gland Imaging
Utilizes Dynamic Meibomian Imaging™ (DMI) to distinctively image meibomian gland structure in high definition.

Please see indication and important safety information on back page.
INDICATIONS AND IMPORTANT SAFETY INFORMATION
for LIPIVIEW® II Ocular Surface Interferometer

Rx ONLY

INDICATIONS
The LipiView® II Ocular Surface Interferometer is an ophthalmic imaging device that is intended for use by a physician in adult patients to capture, archive, manipulate and store digital images of:

• Specular (interferometric) observations of the tear film. Using these images, LipiView® II measures the absolute thickness of the tear film lipid layer.
• Meibomian glands under nearinfrared (NIR) illumination.
• The ocular surface and eyelids under white illumination.

CONTRAINDICATIONS
Contraindications are conditions in which the device should not be used because the risk of use clearly outweighs any benefit. No contraindications have been identified for LipiView® II.

PRECAUTIONS
The following patient conditions may affect the interferometry assessment of a patient's tear film using LipiView® II:

• Use of ophthalmic drops such as artificial tear lubricants, ointments, and medications. Advise patients not not instill oil-based ophthalmic drops (e.g., Soothe®, Restasis®, Systane Balance®) for at least 12 hours prior to device use and not to instill ointments for at least 24 hours prior to device use. Wait at least four (4) hours after the instillation of all other ophthalmic drops prior to device use.
• Soft or rigid contact lens wear. Advise patients to remove contact lenses at least four hours prior to device use.
• Use of oil-based facial cosmetics around the eye. Eye rubbing.
• Recent swimming in a chlorinated pool. Advise patients to not to swim for at least 12 hours prior to device use.
• Any ocular surface condition that affects the stability of the tear film. These conditions include disease, dystrophy, trauma, scarring, surgery, or abnormality.

ADVERSE EFFECTS
There are no known or anticipated adverse effects associated with use of this device.

ATTENTION
Reference the LipiView® II Ocular Surface Interferometer Instructions for Use for a complete listing of indications, warnings, and precautions.

<table>
<thead>
<tr>
<th>LIPIVIEW® II SPECIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
</tr>
<tr>
<td>Dimension</td>
</tr>
</tbody>
</table>